SLN Silence Therapeutics Plc
- Stocks
- Healthcare
- NASDAQ: SLN
Price (delayed)
$5.48
Market cap
$258.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
N/A
Enterprise value
$216.84M
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform
Highlights
Silence Therapeutics's debt has plunged by 100% from the previous quarter and by 100% YoY
The gross profit has soared by 69% YoY and by 14% from the previous quarter
The equity has plunged by 167% YoY but it is up by 16% from the previous quarter
Silence Therapeutics's quick ratio has increased by 9% QoQ but it has decreased by 8% YoY
Silence Therapeutics's net income has plunged by 57% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of SLN
Market
Valuations
Earnings
Shares outstanding
47.19M
Market cap
$258.58M
Enterprise value
$216.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
9.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.92
Revenue
$27.37M
Gross profit
$21.48M
Operating income
-$87.59M
Net income
-$79.4M
EBIT
-$74.36M
EBITDA
-$73.76M
Free cash flow
-$86.53M
Per share
Balance sheet
Liquidity
EPS
N/A
EPS diluted
N/A
Free cash flow per share
-$1.83
Book value per share
-$2
Revenue per share
$0.58
TBVPS
$3.27
Total assets
$165.23M
Total liabilities
$71.08M
Debt
$0
Equity
-$94.16M
Working capital
$133.79M
Debt to equity
0
Current ratio
10.06
Quick ratio
7.74
Net debt/EBITDA
0.57
Margins
Efficiency
Dividend
EBITDA margin
-269.5%
Gross margin
78.5%
Net margin
-290.1%
Operating margin
-320%
Return on assets
-41.5%
Return on equity
N/A
Return on invested capital
-85.6%
Return on capital employed
-49.4%
Return on sales
-271.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLN stock price
How has the Silence Therapeutics stock price performed over time
Intraday
7.66%
1 week
-2.32%
1 month
-14.91%
1 year
-66.75%
YTD
-20.35%
QTD
-5.52%
Financial performance
How have Silence Therapeutics's revenue and profit performed over time
Revenue
$27.37M
Gross profit
$21.48M
Operating income
-$87.59M
Net income
-$79.4M
Gross margin
78.5%
Net margin
-290.1%
The gross profit has soared by 69% YoY and by 14% from the previous quarter
Silence Therapeutics's net income has plunged by 57% YoY and by 11% from the previous quarter
Silence Therapeutics's gross margin has increased by 39% YoY and by 17% QoQ
SLN's operating income is down by 37% YoY
Price vs fundamentals
How does SLN's price correlate with its fundamentals
Growth
What is Silence Therapeutics's growth rate over time
Valuation
What is Silence Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
9.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.92
The equity has plunged by 167% YoY but it is up by 16% from the previous quarter
The P/S is 68% lower than the 5-year quarterly average of 27.3 and 45% lower than the last 4 quarters average of 15.9
SLN's revenue is up by 22% YoY
Efficiency
How efficient is Silence Therapeutics business performance
SLN's ROA is down by 48% YoY and by 21% from the previous quarter
Silence Therapeutics's return on sales has decreased by 39% YoY and by 14% QoQ
SLN's ROIC is up by 15% YoY
Dividends
What is SLN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLN.
Financial health
How did Silence Therapeutics financials performed over time
The total assets is 132% more than the total liabilities
The total assets has contracted by 30% YoY and by 11% from the previous quarter
The total liabilities has declined by 25% year-on-year and by 2% since the previous quarter
Silence Therapeutics's debt is 100% more than its equity
The equity has plunged by 167% YoY but it is up by 16% from the previous quarter
Silence Therapeutics's debt has plunged by 100% from the previous quarter and by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.